Therapeutic opportunities from muscarinic receptor research

Trends in Pharmacological Sciences

Volumn 22, Issue 8, 2001, Pages 409-414

  Eglen, Richard M ^a   Choppin, Agnes ^b   Watson, Nikki ^c  

^a DiscoveRx Corporation   (United States)

^b Deltagen Inc   (United States)

^c UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11 [[4 [4 (DIETHYLAMINO)BUTYL] 1 PIPERIDYL]ACETYL] 5,11 DIHYDRO 6H PYRIDO[2,3 B][1,4]BENZODIAZEPIN 6 ONE; 3,6A,11,14 TETRAHYDRO 9 METHOXY 2 METHYL 12H ISOQUINO[1,2 B]PYRROLO[3,2 F][1,3]BENZOXAZINE 1 CARBOXYLIC ACID ETHYL ESTER; 4 CYCLOHEXYL ALPHA [4 [(4 METHOXYPHENYL)SULFINYL]PHENYL] 1 PIPERAZINEACETONITRILE; 4 DIPHENYLACETOXY 1 METHYLPIPERIDINE; 4 FLUOROHEXAHYDROSILADIFENIDOL; 6 (3 PROPYLTHIO 1,2,5 THIADIAZOL 4 YL) 1 AZABICYCLO[3.2.1]OCTANE; ACETYLCHOLINE; AMYLOID PRECURSOR PROTEIN; ATROPINE; CM 1936; CMI 1145; CYSTRIN CR; DARIFENACIN; DRUG RECEPTOR; HIMBACINE; HTZTP; METHOCTRAMINE; MT 3; MUSCARINIC AGENT; MUSCARINIC M1 RECEPTOR AGONIST; MUSCARINIC M2 RECEPTOR ANTAGONIST; MUSCARINIC RECEPTOR; N [2 [2 (DIPROPYLAMINOMETHYL) 1 PIPERIDYL]ETHYL] 5,11 DIHYDRO 6 OXO 6H PYRIDO[2,3 B][1,4]BENZODIAZEPINE 11 CARBOXAMIDE; NERVE GROWTH FACTOR; OROS; OTILONIUM BROMIDE; OXYBUTYNIN; PINAVERIUM; PIRENZEPINE; RECEPTOR SUBTYPE; SECOVERINE; TEMIVERINE; TIOTROPIUM BROMIDE; TOLTERODINE; TRIPITRAMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VAMICAMIDE; YM 46303; ZAMIFENACIN;

ALZHEIMER DISEASE; ANTINOCICEPTION; BLADDER DISEASE; CHOLINERGIC TRANSMISSION; CHRONIC OBSTRUCTIVE LUNG DISEASE; COGNITIVE DEFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SELECTIVITY; HUMAN; IRRITABLE COLON; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR AFFINITY; REVIEW; SCHIZOPHRENIA; SMOOTH MUSCLE; TRANSGENIC MOUSE; URINE INCONTINENCE;

ANIMALS; HUMANS; MICE; MICE, TRANSGENIC; MUSCARINIC AGONISTS; MUSCARINIC ANTAGONISTS; MUSCLE, SMOOTH; RECEPTORS, MUSCARINIC; RESEARCH;

EID: 0035424943     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(00)01737-5     Document Type: Review

References (51)

1. 1 receptors
2. 2 muscarinic acetylcholine receptor knockout mice
3. 3 subtype
4. 4 muscarinic acetylcholine receptor knockout mice
5. 5 receptors: Genotypes and behavior
6. G protein-coupled receptors: Functional and mechanistic insights through altered gene expression
7. Muscarinic toxins from the green mamba
8. Selective muscarinic receptor agonists and antagonists
9. Pirenzepine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in peptic ulcer disease and other allied diseases
10. Tolterodine, a new antimuscarinic agent: As effective but better tolerated than oxybutynin in patients with an overactive bladder
11. Muscarinic agonists for the treatment of Alzheimer's disease: Progress and perspectives
12. Therapeutic opportunities for muscarinic receptors in the central nervous system
13. Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer's disease
14. Pharmacological basis for functional selectivity of partial muscarinic receptor agonists
15. Release of amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors
16. Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer β/A4 amyloid protein precursor
17. Cholinesterase inhibitors: A new class of psychotropic compounds
18. Pirenzepine distinguishes between different subclasses of muscarinic receptors
19. Muscarinic acetylcholine receptor subtypes in smooth muscle
20. Muscarinic receptor subtypes and smooth muscle function
21. 3-mediated stimulation via Gβγq
22. Decreased adenylyl cyclase protein and function in airway smooth muscle by chronic carbachol pretreatment
23. ca channels in smooth muscle cells by a pertussis-sensitive G protein
24. Muscarinic receptors controlling the carbachol activated nonselective cationic current in guinea-pig gastric smooth muscle cells
25. Acetylcholine activates non-selective cation and chloride conductances in canine and guinea pig tracheal myocytes
26. 2 activation of nonselective cation channels in smooth muscle cells: Calcium and Go/Gi requirements
27. i activation of Rho in human airway smooth muscle cells
28. 2 receptors and β-adrenoceptor subtypes in guinea-pig isolated ileum
29. Differential effects of pertussis toxin on muscarinic responses in isolated atria and smooth muscle
30. 4 receptor knockout mice: Muscarinic receptor function in cardiac and smooth muscle in vitro
31. Pertussis toxin augments β-adrenoceptor relaxation of muscarinic contraction in canine trachealis
32. 2 muscarinic receptors inhibit isoproterenol-induced relaxation of canine airway smooth muscle
33. 3 receptors in guinea-pig trachea: Effects of receptor alkylation
34. Tolterodine - A new bladder selective muscarinic receptor antagonist: Preclinical pharmacological and clinical data
35. Muscarinic receptor antagonists in the treatment of overactive bladder
36. Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability
37. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence
38. 2 antagonists for clinical use
39. A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease
40. 1 receptor agonist activity is not a requirement for muscarinic antinociception
41. 5 receptor subtype: Fact or fiction?
42. The muscarinic M5 receptor: A silent or emerging subtype?
43. 5): High throughput assays in mammalian cells
44. 5 muscarinic receptors expressed in CHO-K1 cells
45. Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies
46. 5 receptors in rat brain
47. Role of tegmental cholinergic neurons in dopaminergic activation, antimuscarinic psychosis and schizophrenia
48. 5 muscarinic cholinergic receptor subtypes in human peripheral blood lymphocytes
49. Muscarinic receptor subtypes in human iris-ciliary body measurement by immunoprecipitation
50. Pharmacological strategies to selectively label and localize receptor subtypes
51. 5 receptor subtypes